Effector Therapeutics Stock Today
| EFTR Stock | USD 2.20 0.04 1.85% |
Performance0 of 100
| Odds Of DistressOver 81
|
Effector Therapeutics is selling at 2.20 as of the 4th of May 2024; that is 1.85 percent increase since the beginning of the trading day. The stock's lowest day price was 2.12. Effector Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Effector Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of April 2024 and ending today, the 4th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of August 2021 | Category Healthcare | Classification Health Care |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company has 3.69 M outstanding shares of which 244.03 K shares are currently shorted by private and institutional investors with about 0.3 trading days to cover. More on Effector Therapeutics
Moving together with Effector Stock
| 0.71 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Effector Stock
| 0.57 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
| 0.45 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.41 | ELVN | Enliven Therapeutics Trending | PairCorr |
Effector Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Effector Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Effector Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Stephen Worland | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Effector Therapeutics report their recommendations after researching Effector Therapeutics' financial statements, talking to executives and customers, or listening in on Effector Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Effector Therapeutics. The Effector consensus assessment is calculated by taking the average forecast from all of the analysts covering Effector Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Effector Therapeutics' liquidity, profitability, solvency, and operating efficiency, Effector Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Effector Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effector Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Effector Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Effector Therapeutics' financial leverage. It provides some insight into what part of Effector Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effector Therapeutics (EFTR) is traded on NASDAQ Exchange in USA. It is located in 142 North Cedros Avenue, Solana Beach, CA, United States, 92075 and employs 14 people. Effector Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Effector Therapeutics's market, we take the total number of its shares issued and multiply it by Effector Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Effector Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.69 M outstanding shares of which 244.03 K shares are currently shorted by private and institutional investors with about 0.3 trading days to cover.
Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99.
Check Effector Therapeutics Probability Of Bankruptcy
Ownership AllocationRoughly 83.0 percent of Effector Therapeutics outstanding shares are held by general public with 2.84 (percent) owned by insiders and only 14.03 % by other corporate entities.
Check Effector Ownership Details
Effector Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Effector Therapeutics jumping above the current price in 90 days from now is about 91.22%. The Effector Therapeutics probability density function shows the probability of Effector Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 4.4469 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Effector Therapeutics will likely underperform. Additionally, effector Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Effector Therapeutics to move above the current price in 90 days from now is about 91.22 (This Effector Therapeutics probability density function shows the probability of Effector Stock to fall within a particular range of prices over 90 days) .
Effector Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Effector Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Effector Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Effector Therapeutics' value.| Instituion | Recorded On | Shares | |
| State Street Corporation | 2023-09-30 | 20.1 K | |
| Callan Capital, Llc | 2023-09-30 | 20 K | |
| Morgan Stanley - Brokerage Accounts | 2023-09-30 | 19.9 K | |
| Vontobel Holding Ltd. | 2023-09-30 | 15 K | |
| Tower Research Capital Llc | 2023-09-30 | 12.3 K | |
| Ubs Group Ag | 2023-09-30 | 9.9 K | |
| Blackrock Inc | 2023-09-30 | 554 | |
| Royal Bank Of Canada | 2023-09-30 | 406 | |
| Wells Fargo & Co | 2023-09-30 | 297 | |
| The Carlyle Group Inc | 2023-09-30 | 4.8 M | |
| Sectoral Asset Management Inc | 2023-09-30 | 2.4 M |
Effector Therapeutics Historical Income Statement
Effector Therapeutics Income Statement is one of the three primary financial statements used for reporting Effector's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Effector Therapeutics revenue and expense. Effector Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Effector Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 05/04/2024, Interest Income is likely to grow to about 1 M, though Interest Expense is likely to grow to (2.8 M). View More FundamentalsEffector Stock Against Markets
Picking the right benchmark for Effector Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Effector Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Effector Therapeutics is critical whether you are bullish or bearish towards Effector Therapeutics at a given time. Please also check how Effector Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Effector Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Effector Therapeutics Corporate Management
Elected by the shareholders, the Effector Therapeutics' board of directors comprises two types of representatives: Effector Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Effector. The board's role is to monitor Effector Therapeutics' management team and ensure that shareholders' interests are well served. Effector Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Effector Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Siegfried Reich | CoFounder Board | Profile | |
| Mayank MD | Chief Officer | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Davide Ruggero | CoFounder Board | Profile | |
| Douglas MD | Chief Officer | Profile | |
| Kevan Shokat | CoFounder Board | Profile |
How to buy Effector Stock?
Before investing in Effector Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Effector Therapeutics. To buy Effector Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Effector Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Effector Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Effector Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Effector Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Effector Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Effector Stock please use our How to Invest in Effector Therapeutics guide.
Already Invested in Effector Therapeutics?
The danger of trading Effector Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Effector Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Effector Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Effector Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Effector Therapeutics is a strong investment it is important to analyze Effector Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Effector Therapeutics' future performance. For an informed investment choice regarding Effector Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Effector Stock analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.37) | Revenue Per Share 0.349 | Quarterly Revenue Growth 1.17 | Return On Assets (0.85) | Return On Equity (9.47) |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.